4-{4-[2-(3,4-difluoro-phenyl)-ethyl]-piperazin-1-yl}-5,6,7,8-tetrahydro-1,3,4b-triaza-fluorene-9-carboxylic acid 2,3-dimethoxy-benzylamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-{4-[2-(3,4-difluoro-phenyl)-ethyl]-piperazin-1-yl}-5,6,7,8-tetrahydro-1,3,4b-triaza-fluorene-9-carboxylic acid 2,3-dimethoxy-benzylamide
• 英文别名: 4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-6,7,8,9-tetrahydro-pyrimido[4,5-b]indolizine-10-carboxylic acid 2,3-dimethoxy-benzylamide；4-[4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl]-N-[(2,3-dimethoxyphenyl)methyl]-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carboxamide
• 化学式: C₃₂H₃₆F₂N₆O₃
• 分子量: 590.673
• InChiKey: DQBOLYOAFHZWDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  43
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  84.8
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-chloro-5,6-tetramethylene-7-cyanopyrrolo<3,2-d>pyrimidin-4-one 在 三乙基硅烷 、 氢氧化钾 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 26.0h， 生成 4-{4-[2-(3,4-difluoro-phenyl)-ethyl]-piperazin-1-yl}-5,6,7,8-tetrahydro-1,3,4b-triaza-fluorene-9-carboxylic acid 2,3-dimethoxy-benzylamide
  参考文献：
  名称：

  Studies on Pyrrolopyrimidines as Selective Inhibitors of Multidrug-Resistance- Associated Protein in Multidrug Resistance

  摘要：

  Multidrug resistance mediated by P-glycoprotein (Pgp) or multidrug-resistance-associated protein (MRP) remains a major obstacle for successful treatment of cancer. Inhibition of Pgp and MRP transport is important for high efficacy of anticancer drugs. While several Pgp inhibitors have entered clinical trials, the development of specific MRP1 inhibitors is still in its infancy. In our screening program, we have identified a pyrrolopyrimidine (4) as a novel and selective MRP1 inhibitor. Subsequent SAR work on the 4-position of the template revealed the phenethylpiperazine side chain as a potent replacement of the benzylthio group of the lead molecule. Introduction of groups at the 2-position seems to have no detrimental effect on activity. Modifications to the nitrile group at the 7-position resulted in the identification of analogues with groups, such as amides, with superior pharmacokinetic profiles. In vivo efficacy has been demonstrated by xenograft studies on selected compounds.

  DOI：

  10.1021/jm031011g

文献信息

• Studies on Pyrrolopyrimidines as Selective Inhibitors of Multidrug-Resistance- Associated Protein in Multidrug Resistance
  作者：Shouming Wang、Adrian Folkes、Irina Chuckowree、Xiaoling Cockcroft、Sukhjit Sohal、Warren Miller、John Milton、Stephen P. Wren、Nigel Vicker、Paul Depledge、John Scott、Lyndsay Smith、Hazel Jones、Prakash Mistry、Richard Faint、Deanne Thompson、Simon Cocks

  DOI：10.1021/jm031011g

  日期：2004.3.1

  Multidrug resistance mediated by P-glycoprotein (Pgp) or multidrug-resistance-associated protein (MRP) remains a major obstacle for successful treatment of cancer. Inhibition of Pgp and MRP transport is important for high efficacy of anticancer drugs. While several Pgp inhibitors have entered clinical trials, the development of specific MRP1 inhibitors is still in its infancy. In our screening program, we have identified a pyrrolopyrimidine (4) as a novel and selective MRP1 inhibitor. Subsequent SAR work on the 4-position of the template revealed the phenethylpiperazine side chain as a potent replacement of the benzylthio group of the lead molecule. Introduction of groups at the 2-position seems to have no detrimental effect on activity. Modifications to the nitrile group at the 7-position resulted in the identification of analogues with groups, such as amides, with superior pharmacokinetic profiles. In vivo efficacy has been demonstrated by xenograft studies on selected compounds.